TabsDetailsBasic DetailsDate Posted: Monday, April 20, 2020Status: In progressDescription: This study aims to sequentially monitor priority drugs for the care of patients hospitalized with COVID-19, including sedatives and drugs used to assist with mechanical ventilation, therapies for respiratory diseases, thrombolytics, anticoagulants, anti-infectives, opioid analgesics, and other drugs used to treat COVID-19. Drug utilization in the outpatient care setting will also be examined. The purpose of this activity is to assess changing patterns of use to support regional assessments of drug use and to assess for drug shortages. Read More Additional InformationInformationTime Period: March 2020 – CurrentPopulation / Cohort: All individualsData Source(s): Select Sentinel Data PartnersRelated LinksRelated Link(s): FDA Sentinel System’s Coronavirus (COVID-19) ActivitiesContributorsWorkgroup Leader(s): Sruthi Adimadhyam, PhD; Judith Maro, PhD; Jeffery Brown, PhD; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MAMichael Nguyen, MD; Grace Chai, PharmD; Corinne Woods, RPh, MPH; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MDWorkgroup Member(s): Jillian Burk, MPH; Katie Haffenreffer; Meg Her, MPH; Casie Horgan, MPH; Jennifer Noble; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MARobert Ball, MD, MPH, ScM; Catherine Corey; Gerald Dal Pan, MD, MHS; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
